Debut Plus

₹277.5

▼ -10.6 -3.68%

As of 23 Oct 2026 · delayed

BSE Listed

LT-ASM · ASM 1
What does LT-ASM · ASM 1 mean?
BSE · Long Term Additional Surveillance Measure (ASM 1)LT-ASM is the joint SEBI/exchange framework for SUSTAINED abnormal price moves (contrast ST-ASM's 5–15-day spikes). Entry is beta-adjusted price variation versus the Nifty (e.g. 3-month high-low above 150% plus the stock's β × index move) along with client-concentration checks. Stages I–IV escalate from a 5% price band through 100% margin to Trade-for-Trade with an additional surveillance deposit. Practical meaning: the exchange still considers the price action abnormal — tighter bands and elevated margins continue even if another measure (like ESM) has lifted. A stock can sit under LT-ASM on both exchanges via either exchange's shortlisting; it is a preventive cost-of-speculation measure, not an adverse finding against the company.Criteria: High 3-month / 12-month high-low price variation, close-to-close price variation, client concentration, number of price-band hits, market-wide position limit and P/E — applied in graded Stages I–IV with escalating margin and price-band curbs.Exchange notice · 2026-10-26

Samrat Pharmachem Ltd. (530125)

Volume: 1,601Avg Vol 1W: 6,392Avg Vol 1M: 2,77852W Range:₹190₹309.85
Key Ratios
Checked 5h ago
Market Cap₹86 Cr
Current Price₹277.5
Previous Close₹288.1
High / Low (52w)₹309.85 / ₹190
Volume1,601
Avg Vol (1W)6,392
Avg Vol (1M)2,778
Stock P/E—
Book Value₹220.67
Dividend Yield0%
ROE-485.78%
ROA-177.62%
Revenue (TTM)—
Revenue Growth—
Profit Margin-75.21%
Total Debt—
Shares Outstanding0 Cr
Face Value—
EPS (TTM)₹0
P/B1.26
Debt / Equity0.15
50 DMA₹238.07
200 DMA₹225.12
Day change-3.68%
SurveillanceLT-ASM · ASM 1
Price Chart
₹277.5▼ 2.56% · 1Y
₹344₹19528K
2025-10-27
2026-10-23

20-day avg volume: 3K shares

Pros
  • Company is almost debt-free.
Cons
  • Company is loss-making at the latest annual result.
Quarterly Results
MetricSept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Revenue₹70 Cr₹64 Cr₹71 Cr₹76 Cr₹79 Cr₹63 Cr₹72 Cr₹80 Cr
EBITDA₹4 Cr₹4 Cr₹0 Cr₹1 Cr₹0 Cr₹0 Cr₹-2 Cr₹2 Cr
Net Profit₹3 Cr₹3 Cr₹0 Cr₹0 Cr₹-1 Cr₹0 Cr₹-2 Cr₹1 Cr
EPS————————
Profit & Loss (Annual)
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue₹112 Cr₹138 Cr₹179 Cr₹222 Cr₹311 Cr₹283 Cr₹287 Cr₹291 Cr
EBITDA₹3 Cr₹7 Cr₹9 Cr₹24 Cr₹24 Cr₹3 Cr₹11 Cr₹-2 Cr
Net Profit₹2 Cr₹4 Cr₹5 Cr₹17 Cr₹17 Cr₹2 Cr₹7 Cr₹-3 Cr
EPS4.9713.7117.2655.6253.83723.02-10.72
Balance Sheet
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets₹40 Cr₹58 Cr₹57 Cr₹85 Cr₹117 Cr₹122 Cr₹121 Cr₹124 Cr
Total Liabilities₹20 Cr₹34 Cr₹28 Cr₹38 Cr₹53 Cr₹57 Cr₹50 Cr₹56 Cr
Equity₹20 Cr₹24 Cr₹30 Cr₹47 Cr₹63 Cr₹65 Cr₹72 Cr₹68 Cr
Total Debt————————
Cash Flow
MetricMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating₹7 Cr₹19 Cr₹0 Cr₹12 Cr₹-9 Cr₹10 Cr
Investing₹-3 Cr₹-1 Cr₹-3 Cr₹0 Cr₹0 Cr₹-3 Cr
Financing₹-2 Cr₹-2 Cr₹10 Cr₹-11 Cr₹0 Cr₹0 Cr
Free Cash Flow₹7 Cr₹19 Cr₹0 Cr₹12 Cr₹-9 Cr₹10 Cr
Shareholding
Promoter 49.09% Institutions 3.24% Public 47.67%
Efficiency & Working Capital
ROCE-2.6%
Interest Coverage-2.1
Dividend Payout—
Debtor Days64 d
Inventory Days55 d
Payable Days54 d
Cash Conversion Cycle65 d
Working Capital Days119 d
Shareholding Details

As of 2026-09-30

Promoter49.1%
FII3.2%
DII0%
Institutions3.2%
Public47.7%
Promoter Pledge0%
No. of Shareholders6,133
Shareholding Pattern

Quarterly — figures in %. Latest 12 quarters.

PeriodDec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026Sept 2026
Promoters48.6%48.6%48.6%49%49.1%49.1%49.1%49.1%49.1%49.1%49.1%49.1%
FIIs0%3.2%3.2%3.2%3.2%3.2%0%3.2%3.2%3.2%3.2%3.2%
DIIs0%0.2%0.2%0.2%0%0%3.2%0%0%0%0%0%
Public51.4%47.9%47.9%47.6%47.7%47.7%47.7%47.7%47.7%47.7%47.7%47.7%
Promoter Pledge0%0%0%0%0%0%0%0%0%0%0%0%
No. of Shareholders8,0657,4787,1696,9846,8446,7856,7526,6996,4886,3116,3306,133
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202603————
Major Shareholders (>1%)
NameCategoryStakeShares
Lalit Damodar MehtaShareholding of Promoter and Promoter Group14%4,31,498
Rajesh Lalit MehtaShareholding of Promoter and Promoter Group12.4%3,83,542
Premal Lalit MehtaShareholding of Promoter and Promoter Group5.7%1,75,281
Kaushal Lalit MehtaShareholding of Promoter and Promoter Group4.5%1,39,065
Jaya Lalit MehtaShareholding of Promoter and Promoter Group3.9%1,19,300
Sangeetha SPublic Shareholding3.3%1,01,010
Rupal Rajesh MehtaShareholding of Promoter and Promoter Group2.7%82,182
Falguni Kaushal MehtaShareholding of Promoter and Promoter Group2.2%66,400
Megh Rajesh MehtaShareholding of Promoter and Promoter Group1.8%54,356
Kalpana Premal MehtaShareholding of Promoter and Promoter Group1.6%50,600
Lalit Kumar V JainPublic Shareholding1.2%37,747
Sharad Kanayalal ShahPublic Shareholding1.1%35,000
Maitri Megh MehtaShareholding of Promoter and Promoter Group0.5%14,543
Board of Directors
NameDesignationYear
Lalit MehtaChairman & Managing Director2025
Rajesh MehtaED / WTD / CFO / Promoter2025
Megh MehtaWhole Time Executive Director2025
Manishkumar PipaliaIndependent Non Exe. Director2025
Sachin KotharyIndependent Non Exe. Director2025
Megha JainIndependent Non Exe. Director2025
Piyush DharodIndependent Non Exe. Director2025
Nishant KankariaCompany Sec. & Compli. Officer2025
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2026₹10533
Corporate Actions
TypeDateValueRemark
forthcoming2026-08-14Board Meetings—
dividend2025-09-18₹1 (10%)Final
forthcoming—Book ClosureAnnual General Meeting
Related-Party Transactions (₹ Cr)
YearSubsidiariesAssociatesJVKMPOthersTotal
2026000101
2026000101
2026000101
Company Information
Incorporated1992
ChairmanLalit Mehta
AuditorShah & Savla LLP
Investor Email[email protected]
🌐 www.samratpharmachem.com ↗

📍 Plot No A2/3445, GIDC Phase IV, Ankleshwar, Gujarat, 393002

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

More stocks

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search